

1 **APOE4, AGE & SEX REGULATE RESPIRATORY PLASTICITY ELICITED BY ACUTE**
2 **INTERMITTENT HYPERCAPNIC-HYPOXIA**

3
4 ^{1,4}Jayakrishnan Nair, ^{1,5}Joseph F. Welch, ¹Alexandria B. Marciante, ²Tingting Hou, ²Qing Lu,
5 ^{1,3}Emily J. Fox* and ¹Gordon S. Mitchell*

6
7 *Co-Senior Authors

8
9 ¹Breathing Research and Therapeutics Center

10 Department of Physical Therapy, University of Florida

11 ²Department of Biostatistics, University of Florida and

12 ³Brooks Rehabilitation, Jacksonville, Florida

13 ⁴Current address: Department of Physical Therapy, Thomas Jefferson University, PA

14 ⁵Current address: School of Sport, Exercise and Rehabilitation Sciences, University of

15 Birmingham, Edgbaston, Birmingham, UK
16
17
18

19 **Correspondence:** Gordon S. Mitchell, PhD
20 Department of Physical Therapy
21 College of Public Health and Health Professions
22 1225 Center Drive
23 Gainesville, FL, USA 32611
24 gsmitch@phttp.ufl.edu
25
26
27

28 **Support:** National Institutes of Health (HL148030 & HL149800), Craig H. Neilsen Foundation
29 (JW), Department of Defense SCIRP Clinical Trial Award and UF Brain and Spinal Cord Injury
30 Trust Fund (BSCIRTF).
31
32
33

34 **Keywords:** intermittent hypercapnic-hypoxia; respiratory neuroplasticity; biomarkers; genetics;
35 *APOE4*, age; sex.
36
37
38

39 **Word count: 4039**

40 **ADDITION TO KNOWLEDGE BASE**

41 Acute intermittent hypoxia (AIH) is a novel rehabilitation strategy to induce functional recovery of
42 respiratory and non-respiratory motor systems in people with chronic spinal cord injury and/or
43 neurodegenerative diseases. Since most AIH trials report considerable inter-individual variability
44 in AIH outcomes, we investigated factors that potentially undermine the response to an
45 optimized AIH protocol, acute intermittent hypercapnic-hypoxia (AIHH), in healthy humans. We
46 demonstrate that genetics (particularly the lipid transporter, *APOE*), age and sex are important
47 biological determinants of AIHH-induced respiratory motor plasticity.

48 **ABSTRACT**

49 **Rationale:** Acute intermittent hypoxia (AIH) is a promising strategy to induce functional motor
50 recovery following chronic spinal cord injuries and neurodegenerative diseases. Although
51 significant results are obtained, human AIH trials report considerable inter-individual response
52 variability. **Objectives:** Identify individual factors (e.g., genetics, age, and sex) that determine
53 response magnitude of healthy adults to an optimized AIH protocol, acute intermittent
54 hypercapnic-hypoxia (AIHH). **Methods:** Associations of individual factors with the magnitude of
55 AIHH (15, 1-min O₂=9.5%, CO₂=5% episodes) induced changes in diaphragm motor-evoked
56 potential amplitude (MEP) and inspiratory mouth occlusion pressures (P_{0.1}) were evaluated in
57 17 healthy individuals (age=27±5 years) compared to Sham. Single nucleotide polymorphisms
58 (SNPs) in genes linked with mechanisms of AIH induced phrenic motor plasticity (*BDNF*,
59 *HTR2A*, *TPH2*, *MAOA*, *NTRK2*) and neuronal plasticity (apolipoprotein E, *APOE*) were tested.
60 Variations in AIHH induced plasticity with age and sex were also analyzed. Additional
61 experiments in humanized (h)*ApoE* knock-in rats were performed to test causality. **Results.**
62 AIHH-induced changes in diaphragm MEP amplitudes were lower in individuals heterozygous
63 for *APOE4* (i.e., *APOE3/4*) allele versus other *APOE* genotypes (p=0.048). No significant
64 differences were observed between any other SNPs investigated, notably *BDNFval/met* (all
65 p>0.05). Males exhibited a greater diaphragm MEP enhancement versus females, regardless of
66 age (p=0.004). Age was inversely related with change in P_{0.1} within the limited age range
67 studied (p=0.007). In *hApoE4* knock-in rats, AIHH-induced phrenic motor plasticity was
68 significantly lower than hApoE3 controls (p<0.05). **Conclusions:** *APOE4* genotype, sex and age
69 are important biological determinants of AIHH-induced respiratory motor plasticity in healthy
70 adults.

71 INTRODUCTION

72 Impaired breathing is a critical health concern for individuals living with lung and/or
73 neuromuscular injury or disease. Repetitive exposures to brief episodes of low inspired O₂
74 (acute intermittent hypoxia, AIH) induces respiratory motor plasticity, which can be harnessed to
75 improve respiratory and non-respiratory motor function [1]. However, human studies published
76 to date exhibit considerable variability in AIH responses; – 30-40% of all participants are low
77 responders to AIH [2]. The fundamental goal of this study was to identify genetic biomarkers
78 and the influence of age and sex on individual AIH responses in healthy humans.

79 In a published companion article, we reported that intermittent exposure to concurrent
80 hypoxia and hypercapnia (AIHH: acute intermittent hypercapnic-hypoxia; ~9.5% inspired O₂;
81 ~4.5% inspired CO₂) elicited robust facilitation of diaphragm motor-evoked potential, MEP,
82 reflection volitional pathways to phrenic motor neurons, and mouth occlusion pressure in 100
83 msec (P_{0.1}), reflecting automatic ventilatory control, in healthy adults [3]. Combined hypoxia and
84 hypercapnia are more effective at triggering respiratory motor plasticity in humans [4, 5],
85 possibly because greater carotid chemoreceptor activation augments serotonergic raphe neuron
86 activity more than hypoxia alone [6, 7], and/or direct activation of raphe neurons by hypercapnia
87 [8], thereby enhancing cell signaling cascades that strengthen synapses onto phrenic motor
88 neurons. Consistent with published human AIH trials [2], ~40% of participants respond
89 minimally to AIHH (defined as <25% increase in diaphragm MEP amplitudes). Since clinical
90 trials investigating rehabilitation interventions often fail due to response heterogeneity [9-11],
91 identifying biomarkers associated with individual responses is essential for successful large-
92 scale clinical trials [2].

93 Genomic analysis has improved healthcare precision in the treatment of cancer and
94 other clinical disorders [12]. Similar focus on identifying genetic biomarkers to align genetic
95 profiles or individual characteristics (age or sex) with the most effective rehabilitation strategies
96 is lacking. Genetic factors regulate AIH-induced serotonin [13] and BDNF-dependent [14]
97 phrenic motor plasticity in rats [15, 16], leading to the hypothesis that dysfunctional genes

98 affecting peripheral chemosensitivity, serotonergic function and/or BDNF/TrkB signaling
99 undermine AIH-induced respiratory plasticity in humans (Figure 1). Dysfunctional genes that
100 undermine neuroplasticity in other regions of the central nervous system, such as alleles coding
101 for the lipid transporter apolipoprotein E (*APOE*), may also contribute to lower individual
102 responses. For example, the *APOE4* isoform is associated with Alzheimer's disease, limited
103 recovery from neural injury, impaired glutamate receptor function and limited BDNF availability
104 [17].

105 Advancing age and sex are other characteristics that differentially affect AIH-induced
106 phrenic motor plasticity in rats [18, 19]. An age-dependent sexual dimorphism could contribute
107 to AIH and AIHH response variability in humans. Clear links between genetics, age and sex with
108 AIH/AIHH-induced phrenic motor plasticity in rodents informs our hypothesis that human
109 response heterogeneity to AIHH [3] is linked with dysfunctional single nucleotide polymorphisms
110 (SNPs) in molecules known to regulate AIH-induced phrenic motor plasticity (e.g. the
111 *BDNFval/met* mutation) as well as age and sex.

112

113 **PROTOCOL AND METHODS**

114 The present study was approved by the Institutional Review Board (IRB202000711) for human
115 studies, and the Institutional Animal Care and Use Committee (IACUC202110316) for rat
116 studies at the University of Florida. Human procedures were performed in accordance with the
117 Declaration of Helsinki, except for registration in a database. This study is part of a larger
118 research effort directed at optimizing AIH protocols with the use of AIHH in humans (see 3). For
119 more information concerning methodological approaches and results, see supplementary
120 material and Welch et al. [3].

121

122 **Participants**

123 Seventeen participants (age range=20-40 years, mean age=27±5 years, 9 females) signed a
124 written informed consent form to participate in the study [3]. Participants with known

125 cardiovascular, respiratory, neurological, or infectious disease/illness, seizures, migraine (in the
126 last 6 months), and/or metallic implants around the head, chest or shoulder region were
127 excluded from the study. Females were screened for pregnancy. Participants were asked to
128 refrain from caffeine consumption 8 hours prior to testing.

129

130 **Experimental Design**

131 A detailed description of the experimental protocol and outcome measures are described
132 elsewhere [3] and in supplementary material. Briefly, in a single-blind, cross-over sham-
133 controlled experiment, participants received on 2 days (separated by ≥ 3 days): AIHH (15, 1-min
134 hypercapnic-hypoxia episodes with 1.5 min intervals breathing room air) and normocapnic-
135 normoxia (Sham control). During AIHH, participants inspired from a Douglas bag filled with
136 $\sim 9.5\%$ O₂ and 4.5% CO₂ (balance N₂). Participants breathed ambient air during Sham.

137

138 **Measures of Respiratory Neuroplasticity**

139 Diaphragm MEPs induced by transcranial magnetic stimulation were used to assess cortico-
140 diaphragmatic neurotransmission [3, 20, 21]. Spontaneous respiratory drive was estimated
141 using mouth occlusion pressure in 0.1 seconds (P_{0.1}) during resting breathing [22]. Tidal
142 volume, breathing frequency and minute ventilation were also measured before (Pre), during
143 and after (Post) AIHH and Sham. The magnitude of AIHH-induced plasticity was quantified as
144 %-change from baseline $[(\text{Post}-\text{Pre})/\text{Pre} \times 100]$.

145

146 **Candidate Gene and Single-Nucleotide Polymorphism Selection**

147 Based on known roles of molecules in AIH-induced phrenic motor plasticity and a minimum
148 population penetrance of 10% [3, 23, 24], we screened for 9 SNPs in genomic DNA extracted
149 from the subject's saliva. Seven candidate genes (Figure 1; Table 1) included autosomal SNPs
150 in: apolipoprotein (*APOE4*, SNP IDs: rs429358 [T>C] and rs7412 [T>C]), prevalence: *APOE4*
151 homozygous $\sim 11\%$, [17, 25, 26], *APOE3/4* heterozygous $\sim 15-25\%$ [27, 28]; brain-derived

152 neurotrophic factor (*BDNF**val/met*, SNP ID: rs6265 [C>T], prevalence ~30-50% [14, 29-31]);
153 neurotrophic receptor tyrosine kinase 2 (*NTRK2*, SNP ID: rs1212171 [C>T], prevalence ~50%
154 [32-34]); tryptophan hydroxylase 2 (*TPH2*, SNP ID: rs7305115, [A>G], prevalence 38-58% [35,
155 36]); 5-hydroxytryptamine receptor 2A (*HTR2A*, SNP ID: rs6313 [A>G], prevalence ~42% [37]);
156 and, paired-like homeobox 2B (*PHOX2B*, SNP ID: rs16853571 [A>C], prevalence ~6-14% [38]).

157 SNPs in sex chromosomes include male monoamine oxidase A (*MAOA*, SNP ID:
158 rs5906957 [A>G], prevalence ~36% in male [39]) and female *MAOA* gene (SNP ID: rs1137070
159 [C>T], prevalence ~31% in female [40]).

160

161 **DNA Extraction and Genotyping**

162 **Saliva collection and storage.** Participants drool saliva was collected in a DNA/RNA shield-
163 saliva collection kit (Genesee Inc.). Genomic (g) DNA from the saliva was extracted using a spin
164 column-based DNA isolation kit (Zymo Quick-DNA Miniprep Kit Cat# D4069). Extracted gDNA
165 was quantified via spectrophotometry (NanoDrop Model 2000C, Thermo Fisher Sci.) and
166 sample purity was estimated by absorbance ratio of A260/A280 (sample range: ≥ 1.8 -2.0).
167 Extracted DNA was diluted to 1ng/ul concentration and used as templates in real time
168 quantitative polymerase chain reaction (PCRs; QuantStudio3; Applied Biosystems). A 5' to 3'
169 exonuclease assay in TaqMan (Applied Biosystems) was used to amplify the gene SNP of
170 interest. SNP genotyping calls were performed with TaqMan Genotyper Software (Thermo
171 Fisher Sci. Inc). Human DNA samples with known genotype from Coriell Institute's Medical
172 Research Repository were used as control identifier for TaqMan Genotyper Software.

173

174 **Genotype coding used for regression analysis.** Prior to applying linear model regression for
175 SNP loci analysis, genotypes were recoded: 1) for *BDNF*, the "T" allele number was counted; 2)
176 for *APOE*, the number of allele "C" in 2 loci, i.e. rs429358, and rs7412 were counted, and if the
177 number was ≥ 3 , the new variable was set to 1 (otherwise 0); 3) for *NTRK2*, the number of allele
178 'T'; 4) for *HTR2A*, the number of allele 'G'; 5) for *TPH2*, the number of allele 'G' was counted.

179 Since *MAOA* SNP loci (male, rs5906957 and female, rs1137070) have different localizations on
180 the X chromosome, we stratified results based on sex and analyzed them separately. Data from
181 *PHOX2B* SNP (rs16853571) was omitted in the analysis due to lack of gene variation in our
182 study sample. For SNP locus analysis, variables age and sex were considered as covariates.

183

184 **Humanized *ApoE* Knock-in Rat Experiments**

185 Based on the observed association between *APOE3/4* and impaired AIHH-induced diaphragm
186 plasticity in humans, we performed follow up experiments in adult male Sprague-Dawley rats
187 (345-385g; Envigo, IN, USA) with homozygous knock-in humanized *ApoE3* (*hApoE3*; ID #395,
188 n=4) or *ApoE4* (*hApoE4*; ID #359, n=3). Neurophysiology experiments were performed in
189 urethane anesthetized, paralyzed and ventilated rats at times consistent with human AIHH
190 treatments (*i.e.*, active phase; 12 a.m. in rats [41]). The primary outcome measure was the
191 amplitude of integrated phrenic nerve bursts (1-min averages), taken before, during, and 30, 60
192 and 90 min after exposure to an AIHH protocol comparable to that delivered to humans (15, 1
193 min episodes of hypercapnic-hypoxia; 1.5 min intervals). Experimental details of these
194 neurophysiology experiments are provided in the supplemental section and elsewhere [42-44].

195

196 **Statistics**

197 The quality of SNP genotype data was analyzed for deviations from Hardy Weinberg equilibrium
198 using both the Exact Test and Chi-Squared Test. A single-locus analysis was used to assess
199 the association of each SNP with treatment outcome [45]. After adjusting for age and sex, the
200 association between %-change from baseline and SNPs was explored using a linear regression
201 model in R software [46]. A detailed description of SNP genotype coding used for liner
202 regression analysis is provided in the supplementary section. The association of age and sex
203 with primary dependent variables (diaphragm MEPs and P0.1) were analyzed using a liner
204 regression model.

205 Peak phrenic nerve burst amplitude was averaged over 1 min immediately before blood
206 samples were taken at baseline and at 30, 60 and 90 min post-AIHH. Phrenic nerve burst
207 amplitude was analyzed using absolute values and normalized as a percent change from
208 baseline. Phrenic responses were analyzed using a two-way repeated measures ANOVA with
209 Tukey's *post-hoc* analysis (SigmaPlot, v12.0; Systat Software, San Jose, CA). Differences were
210 considered significant when $p < 0.05$. Data are expressed as mean \pm SD.

211

212 **RESULTS**

213 Demographics, genotype and pre to post %-change in primary dependent variables (MEP and
214 P_{0.1}) following AIHH and Sham for each participant are presented in Table 1. A detailed report
215 of the cardiorespiratory responses during AIHH exposure in the same set of individuals is
216 presented in a companion paper [3]. Only genetics, age, and sex effects on diaphragm MEP
217 amplitudes and P_{0.1} are presented here; age and sex effects are presented in supplementary
218 material.

219

220 **Gene SNPs Associated with Dysfunctional AIHH-Induced Plasticity**

221 No departure from Hardy-Weinberg equilibria was observed within the screened autosome or
222 sex chromosome loci. For brevity, and due to their associations with AIHH-induced plasticity, we
223 report results in this manuscript for *BDNFval/met*, *APOE4* and *TPH2* SNPs. A complete
224 summary of all SNPs and multiple regression analyses for %-change in diaphragm MEP
225 amplitudes and P_{0.1} are provided in Tables 2A and 2B. One participant (participant ID: S06;
226 Table 1) with *TPH2* homozygous major "A" allele was identified statistically (Cook's D >4) as the
227 most influential data point in the regression for %-change in diaphragm MEP amplitudes (Figure
228 2). Therefore, data from S06 was not included in any analysis except for *TPH2* group analysis.

229

230 ***BDNFval/met (rs6265)***. Eight participants were heterozygous, and none were homozygous for
231 the *BDNFval/met* allele. No significant difference was observed between *BDNFval/met*

232 heterozygotes and individuals without *BDNF*val/met for %-change in diaphragm MEP
233 amplitudes (Figure 2A; Table 2, p=0.290, t=1.090) or P0.1 (Figure 2B; Table 3, p=0.885,
234 t=0.150).

235

236 ***APOE (rs429358 and rs7412)***. Five participants were heterozygous for *APOE4* (i.e., *APOE3/4*);
237 none were homozygous for *APOE4*. The *APOE3/4* genotype was associated with diminished %-
238 change in diaphragm MEP amplitudes following AIHH (Figure 2C, Table 2, p=0.048, t=-2.187).
239 The %-change in diaphragm MEP amplitudes was 38% lower in individuals with *APOE3/4*
240 (*APOE3/4+*) versus individuals carrying other allelic *APOE* isoforms (e.g., *APOE3/4*). In contrast,
241 no significant association between *APOE3/4+* and %-change in P0.1 was observed (Figure 2D;
242 Table 3, p=0.159, t=1.490).

243

244 ***TPH2 (rs7305115)***. Two participants were homozygous for the *TPH2* major “A” allele (participant
245 ID: S01 and S06), 8 participants were heterozygous and 7 homozygous for the dysfunctional
246 minor “G” allele. Although not statistically significant, there was a marginal association between
247 the presence of at least 1 “G” allele and %-change in diaphragm MEP amplitudes (p=0.063, t=-
248 2.030). The coefficient of the *TPH2* gene was -0.251, meaning responses were 25.1% lower
249 than average with 1 “G” allele. This effect was primarily influenced by the outlier participant
250 (S06) who was homozygous for “A” allele. No association was observed between *TPH2* locus
251 variants and P0.1 (p=0.990, t=0.002).

252

253 **Age-Sex Dimorphism in Diaphragm MEPs**

254 No significant relationship was found between age and %-change in diaphragm MEP amplitude
255 following AIHH (Figure 4A; r=0.08, 95% CI= -2.47 to 3.32, p=0.758). No significant differences
256 in diaphragm MEP amplitude change were observed with age in males (Figure 4B; r=0.24, 95%
257 CI= -1.18 to -0.4.24, p=0.217) or females (Figure 4B; r=-0.01, 95% CI= -5.75 to 4.38, p=0.752).

258 However, males had significantly higher %-change in diaphragm MEP amplitudes *versus*
259 females, regardless of age (mean difference=37±10.8%, F=12.17, p=0.004).

260

261 **Age-Sex Dimorphism in P0.1**

262 A negative correlation was observed between %-change in P0.1 and participant's age, despite
263 the limited age range included in this study (Figure 4C; r=-0.64, 95% CI=-0.85 to -0.23,
264 p=0.007). Each year of increasing age corresponded to a 3.9% decrease in P0.1 response. The
265 decline in P0.1 with age was explained by male (Figure 4D; r=-0.73, 95% CI= -0.95 to -0.07,
266 p=0.036) *versus* female responses (Figure 4C; r=-0.29, 95% CI= -0.83 to -0.52, p=0.480) to
267 AIHH. Regression slope (F=1.77, p=0.210) and intercept (F=1.5, p=0.240) for %-change in P0.1
268 were not significantly different between males and females.

269

270 **Humanized ApoE Knock-In Rats and AIHH Induced Phrenic Long-Term Facilitation**

271 Figure 3A shows average phrenic nerve burst amplitudes during and following AIHH. Baseline
272 phrenic nerve amplitudes were not different between groups (*hApoE3*: 0.023±0.007 V; *hApoE4*:
273 0.022±0.013 V). On the other hand, AIHH elicited significant phrenic long-term facilitation in
274 *hApoE3* (p=0.025 vs. baseline), but not in *hApoE4* rats (p=0.995). A significant interaction
275 between genotype and time post-AIHH was observed in phrenic long-term facilitation magnitude
276 (Figure 3B; F=5.93, p=0.007). AIHH-induced phrenic long-term facilitation in *hApoE3* rats was
277 significantly greater than *hApoE4* at 30 min (p=0.004), 60 min (p=0.002) and 90 min (p<0.001)
278 post-AIHH. Arterial CO₂ partial pressures at baseline (*hApoE3*: 43.9 ± 1.5 mmHg; *hApoE4*:
279 45.7±1.2 mmHg) and 90 min post-AIHH (*hApoE3*: 44.4±1.6 mmHg; *hApoE4*: 46.2±0.4 mmHg)
280 were not different.

281

282 **DISCUSSION**

283 We investigated the role of genetics, age and sex on AIHH-induced respiratory motor plasticity
284 of both cortical (presumably volitional) diaphragm MEPs and brainstem automatic (P0.1) neural

285 pathways in healthy adults. We report increased diaphragm MEP amplitudes following AIHH are
286 diminished in people heterozygous for the *APOE4* allele and unaffected in *BDNFval/met*
287 heterozygotes. Regardless of age, the %-change in diaphragm MEP amplitudes following AIHH
288 is greater in males *versus* females, whereas sex does not influence the magnitude of change in
289 P0.1. Finally, despite the limited age range in this study (20-40 years), there was a negative
290 correlation between age and P0.1 facilitation. Neurophysiological experiments in *hApoE3* and
291 *hApoE4* knock-in rats confirmed a causal relationship between *hApoE4* genotype and impaired
292 phrenic motor plasticity.

293

294 **SNPs and AIH/AIHH Induced Plasticity**

295 To investigate SNPs that influence AIH/AIHH-induced respiratory motor plasticity, a panel of
296 genes was assessed chosen based on their known links to phrenic motor plasticity in rodents,
297 including SNPs linked to serotonin synthesis (*TPH2*), clearance (*MAOA*), or receptors (*HTR2A*),
298 a key neurotrophic factor (*BDNF*), and its high affinity receptor (*NTRK2*), as well as
299 chemoreceptor function (*PHOX2B*). A seventh gene, *APOE4* was added to the panel due to its
300 association with impaired neuroplasticity [17], including AIH-induced phrenic long-term
301 facilitation [47].

302 No association was found between 6 gene SNPs and AIHH-induced respiratory motor
303 plasticity in the humans studied here. Tryptophan hydroxylase-2 (*TPH2*) is the rate limiting
304 enzyme for serotonin synthesis [36]; presence of a “G” allele in exon 7 of the *TPH2* gene is
305 associated with reduced serotonin bioavailability [35, 48]. An apparent (but. not significant;
306 $p=0.063$) ~25% diminished response in the presence of 1 *TPH2* “G” allele requires further study.

307 Since BDNF is both necessary and sufficient for AIH-induced phrenic motor plasticity in
308 rats [14], we hypothesized that the dysfunctional *BDNFval/met* allele undermines plasticity.
309 *BDNFval/met* is a common missense single nucleotide C>T polymorphic mutation at codon 66
310 of *BDNF* gene, resulting in amino acid methionine (Met) substituting valine (Val).
311 *BDNFval66met* or *BDNFval/met* mutation, impairs the pro-domain region of BDNF protein,

312 disrupting the normal trafficking of mature BDNF from neuron soma to dendrites [49-51]. This
313 dysfunctional *BDNF* SNP is associated with reduced exercise-induced plasticity and functional
314 recovery in people with spinal cord injury or traumatic brain injury [31, 52, 53]. However,
315 contrary to our hypothesis, no association between *BDNFval/met* mutation and AIHH-induced
316 respiratory motor plasticity was found (Figure 2A). We speculate that in healthy adults, one fully
317 functional allele is sufficient to meet physiological demands and/or enable adequate responses
318 to certain physiological stimuli, such as AIHH. Since no participants had homozygous
319 *BDNFval/met* mutation, we cannot rule out an association between homozygous *BDNFval/met*
320 and respiratory motor plasticity.

321 *APOE* is a triglyceride rich low-density lipoprotein that facilitates lipid transport between
322 cells. *APOE* is highly expressed in the central nervous system, with 3 common human isoforms
323 (E2, E3 and E4) [54]. With respect to neuroplasticity, the T to C nucleotide substitutions at
324 *APOE* loci (*APOE4*) leads to arginine substitutions in the 112 and 159 positions (SNPs
325 rs429358 and rs7412), and is the most consequential SNP mutation for neuroplasticity.
326 Homozygous *APOE4* allele is present in 11-14% of people, whereas heterozygous *APOE3/4*
327 allele is found in about 15-25% of people [27, 28]; In this group of study subjects, we observed a
328 slightly higher percentage of *APOE3/4* heterozygotes (~29%), which may be attributed to our
329 small sample size. Individuals with the *APOE4* allele experience diminished motor recovery
330 following spinal cord injury *versus* other *APOE* alleles [25]. *APOE4* protein isoform has been
331 hypothesized to impair AIH-induced plasticity [47] as it reduces NMDA and AMPA receptor
332 recycling in the post-synaptic membrane, and limits BDNF availability. A recent study in
333 transgenic mice with knock-in *hApoE4* suggested that *APOE4* protein isoform is associated with
334 impaired AIH-induced respiratory motor plasticity [47], consistent with our observation that at
335 least 1 dysfunctional *APOE4* allele was associated with 38% reduction in AIHH-induced
336 diaphragm MEP facilitation. Thus, stratifying participants based on Mendelian randomization of
337 known genetic risk factors may be critical for success of large phase II and III clinical trials
338 investigating the efficacy of AIH/AIHH [56].

339

340 **Causal link between *APOE4* on AIHH-induced respiratory motor plasticity**

341 To demonstrate a causal link between *APOE4* and AIHH-induced respiratory motor plasticity,
342 we performed neurophysiology experiments in *hApoE4* and *hApoE3* knock-in rats using a nearly
343 identical AIHH protocol to humans (15, 1-minute episodes of hypercapnic-hypoxia during the
344 night, or the active phase for rats). Whereas rats with *hApoE3* manifested robust AIHH-induced
345 phrenic long-term facilitation (~60% increase at 90 min post AIHH), *hApoE4* rats failed to
346 express significant plasticity. Thus, *APOE4* undermines AIHH-induced respiratory motor
347 plasticity in rats. Our data support an earlier report by Strattan and colleagues [47] where
348 *hApoE4* mice failed to express AIH-induced respiratory plasticity, despite study differences such
349 as species (mice *versus* rats), plasticity-inducing protocol (AIH *versus* AIHH) and time of day
350 (rest vs active phase).

351 Although the mechanistic link between a dysfunctional *APOE4* allele and reduced spinal
352 plasticity is not yet known, we suggest a few plausible hypotheses. *APOE4* protein isoform
353 converts microglia to a pro-inflammatory phenotype [26], which may undermine phrenic motor
354 plasticity [55]. Further, the observation that *hApoE4* mice exhibit more extensive perineuronal
355 nets after spinal cord injury [47] suggests an alternate mechanism, and suggests a distinct
356 therapeutic target to mitigate the dysfunctional effects of *APOE4* genotype. Future studies
357 investigating *APOE4* induced pathophysiology may reveal additional targets to unlock AIHH
358 induced neuroplasticity in *APOE4* carriers.

359 Unlike the association of *APOE3/4* and *TPH2* SNPs with reduced diaphragm MEP
360 responses following AIHH, no similar association was found between these genotypes and P0.1.
361 This difference could be due to distinctions in the neuronal pathways utilized with transcranial
362 magnetic stimulation (reflecting volitional control of breathing) *versus* automatic (bulbosplinal)
363 pathways to phrenic motor neurons and/or the correlation between participant' age and P0.1
364 facilitation (see below), which likely obscured the influence of genetic factors.

365

366 **Age-Sex Dimorphism in AIHH Induced Plasticity**

367 Decades of rodent work demonstrate a link between age, sex and AIH-induced phrenic motor
368 plasticity [18, 19, 56, 57]. Although our results are generally consistent with prior observations in
369 rats, there were some interesting differences.

370

371 **Diaphragm MEP responses.** We observed that in healthy adults, regardless of age,
372 corticospinal plasticity (i.e., diaphragm MEPs) was significantly greater in males versus females
373 (mean difference= $37 \pm 10.8\%$). Sex differences in the neural control of breathing have been
374 observed during ventilatory challenges [58, 59] and the capacity for respiratory neuroplasticity
375 [60, 61]. These sex differences could be caused by ovarian hormones that affect
376 neurotransmission. In rats, hippocampal long-term potentiation is induced more readily in males
377 *versus* females due to excitatory effects of testosterone [62, 63]. In females with normal
378 menstruation, circulating progesterone reduces cortical excitability [64, 65]. During the luteal
379 phase of menstrual cycle (high progesterone), increased inhibition and decreased facilitation of
380 TMS responses are observed, which is indicative of increased GABAergic effects from
381 progesterone metabolites [65]. In contrast, there is increased cortical facilitatory activity during
382 the mid-follicular phase of the menstrual cycle (low progesterone, high estrogen). Thus, our
383 results are in line with previous literature.

384

385 **P0.1 responses.** A significant decrease in AIHH-induced P0.1 plasticity was observed with
386 increasing age; each year of age in the range studied (20-40 years) led to a fall in P0.1 plasticity
387 of $\sim 3.9\%$. This age-related drop was more pronounced in males than females. Negative
388 pressure generation in 0.1 seconds of an occluded inspiration reflects respiratory
389 neuromechanical drive prior to influences from breath-related sensory feedback, such as from
390 lung or chest wall receptors [22]. Explanations for diminished AIH/AIHH-induced neuroplasticity
391 with age observed in the present study include: 1) decreasing sex hormone

392 (testosterone/estrogen) levels [19, 66]; 2) diminished serotonergic function [18] and/or 2)
393 increased extracellular CNS adenosine levels [67, 68].

394 Since changes in P0.1 reflect automatic control of breathing, it may be more equivalent to
395 rodent phrenic long-term facilitation versus MEPs. In rats, phrenic long-term facilitation
396 decreases as males reach middle-age [19], but increases in middle-aged females (when
397 normalized for stage of the estrus cycle) [69]. Estrogen suppresses pro-inflammatory microglial
398 activities [70] and even mild inflammation impairs phrenic long-term facilitation [55, 71, 72].
399 Testosterone is necessary for phrenic long-term facilitation in males because it is a substrate for
400 aromatase-dependent CNS estrogen formation [66]. In male rats, testosterone peaks at ~2-6
401 months of age, equivalent to ~18-40 years in humans [73-75], which is then followed by a
402 gradual decline, similar to human males in the ~40-60 year age range [76, 77]. Since the age of
403 our participants ranged from 20-40 years, reduced serum sex hormone levels are unlikely to
404 explain variance in P0.1 responses; furthermore, the %-change in P0.1 was not significantly
405 different between sexes in this study. Adenosine is another major regulator of AIH-induced
406 phrenic motor plasticity in rats [78, 79]. Extracellular adenosine levels in the central nervous
407 system increase with age – greater adenosine-dependent inhibition of phrenic motor plasticity
408 may occur [80], potentially explaining reduced P0.1 plasticity with age in our study.

409

410 **LIMITATIONS**

411 Rather than more common “omics” approaches, we selected a panel of 7 genes and 9 SNPs to
412 investigate as a potential biomarker based on known roles of the relevant molecules in AIH-
413 induced respiratory motor plasticity, and the relative penetrance of the SNPs in humans.
414 Although this list does not include all SNPs that could affect AIH/AIHH-induced plasticity, we
415 verify that genetic factors regulate AIHH-induced plasticity in humans, particularly *APOE4*. This
416 is the first study to link *APOE4* with spinal, respiratory motor plasticity in humans. Due to the
417 number of potential SNPs that could be investigated, adequate correction for multiple

418 comparisons will remain a challenge. Further, it is important to increase the age range studied
419 beyond 40 years and to extend investigations to people living with disease or injury.

420

421 **CONCLUSIONS**

422 We provide evidence that the *APOE4* allele, age and sex are important biological determinants
423 of AIHH-induced respiratory motor plasticity in humans. The presence of one dysfunctional
424 *APOE4* allele undermines cortico-spinal respiratory motor plasticity. Experiments using
425 humanized *APOE4* knock-in rats support a causal relationship between *APOE4* and impaired
426 AIHH-induced respiratory motor plasticity. Contrary to our original hypothesis, no evidence was
427 found for diminished plasticity in individuals with *BDNFval/met* mutations, although no
428 homozygous subjects were included in this analysis. Regardless of age, males exhibited greater
429 AIHH-induced cortico-spinal plasticity *versus* females; conversely, AIHH-induced plasticity in
430 P0.1 is negatively associated with increasing age – an effect that is more pronounced in males
431 than females. Thus, age, sex and genetic factors should all be considered when attempting to
432 differentiate responders from non-responders in clinical trials investigating therapeutic use of
433 AIH/AIHH in individuals with spinal cord injury or other neurological conditions. With such
434 information in hand, it may be possible to refine rehabilitation protocols and/or provide
435 individualized treatment strategies.

436 **ACKNOWLEDGEMENTS**

437 The authors thank Carter Lurk and Patrick Argento for their technical assistance with sample
438 management and genotyping; both have reviewed the final manuscript and provided permission
439 for this acknowledgement.

440 **LEGENDS**

441 **Figure 1: Conceptual diagram depicting cell signaling mechanisms (and candidate**
442 **biomarker genes) for acute intermittent hypercapnic-hypoxia (AIHH) induced respiratory**
443 **motor plasticity.** The panel of SNPs with a population prevalence of >10% were tested for
444 association with reduced AIHH-induced plasticity in humans. These include 6 SNPs in genes
445 involved in AIH cell signaling: (1) raphe chemosensitive cells (*PHOX2B*), (2) serotonin
446 precursors in the central nervous system (tryptophan hydroxylase-2, *TPH-2*), (3) serotonin
447 clearance enzyme (monoamine oxidase A, *MAOA*), (4) serotonin-2A receptors (*HTR2A*), (5)
448 brain-derived neurotrophic factor (*BDNF*) and (6) TrkB receptors (*NTRK2*). A seventh
449 dysfunctional SNP in neuroplasticity related gene, APOE (*APOE4*), was also tested for
450 association.

451
452 **Figure 2: Relative (%-change from baseline) changes in diaphragm motor-evoked**
453 **potential (MEP) amplitudes and mouth occlusion pressure (P_{0.1}) in individuals with**
454 ***BDNF*val/met (panels A and B) and *APOE*_{3/4} (panels C and D) SNP.** No associations were
455 observed between individuals with *BDNF*val/met and the change in MEP amplitudes (panel A)
456 or P_{0.1} (panel B). Individuals with dysfunctional *APOE*_{3/4} allele were associated with a
457 significantly lower AIHH-induced change in MEP amplitude (t=-2.28, p=0.048, panel C).
458 However, no association between *APOE*_{3/4} and AIHH-induced P_{0.1} responses were observed
459 (panel D). Δ=change. *p<0.05. Results expressed as mean ± SD.

460 ⬠ = participant (S6) was identified as the most influential point (Cook's D >4) in the %-change
461 in diaphragm MEP amplitudes, therefore, the data was not included in group analyses.

462
463 **Figure 3: AIHH elicits phrenic long-term facilitation in hApoE3 but not hApoE4 knock-in**
464 **rats.** Panel A shows average traces of phrenic nerve amplitude for hApoE3 (n=4; gray) and
465 hApoE4 (n=3; black) knock-in rats, *p<0.050 vs baseline. Panel B phrenic burst amplitude (%-

466 change from baseline) in hApoE3 (gray circles) and hApoE4 (black circles) rats, +p<0.005
467 versus hApoE4. Δ =change. Results expressed as mean \pm SD.

468

469 **Figure 4: Relationship between age and sex on the magnitude (%-change from baseline)**
470 **of change in diaphragm motor-evoked potential amplitudes (MEP, panels A and B), and**
471 **mouth occlusion pressure in 0.1 seconds (P0.1, panels C and D) following AIHH.** No
472 association between age and the magnitude of change in diaphragm MEP amplitudes was
473 observed (panel A). Regardless of age, males (black line, panel B) had significantly greater
474 responses in MEP amplitudes versus females (gray line, panel B). The magnitude of change in
475 P0.1 reduced significantly with age (panel C); however, the decline was more pronounced in
476 males ($r=-0.73$, $p=0.036$, black line, panel D) versus females ($r=-0.29$, $p=0.480$, gray line, panel
477 D). Δ =change. * $p<0.05$. Results expressed as mean \pm SD.

478 \blacklozenge = participant (S6) was identified as the most influential point (Cook's $D >4$) in the %-change
479 in diaphragm MEP amplitudes, therefore, the data was not included in group analyses.

480


481 **Table 1. Demographics and SNP genotype classification details.** Includes individual
482 participants' %-change from baseline in diaphragm motor-evoked potential amplitudes (MEP)
483 and mouth occlusion pressure (P0.1) following AIHH and Sham exposures. Genotype letters in
484 bold and underlined text indicate dysfunctional allele.

485

486 **Table 2. Association of SNPs with %-change from baseline in diaphragm motor-evoked**
487 **potential amplitudes (MEP).** * $p<0.05$.


488

489 **Table 3. Association of SNPs with %-change from baseline in mouth occlusion pressure**
490 **in 0.1 seconds (P0.1).** * $p<0.05$.




491 **Figure 1: Conceptual diagram depicting cell signaling mechanisms (and candidate**
 492 **biomarker genes) for acute intermittent hypercapnic-hypoxia (AIHH) induced respiratory**
 493 **motor plasticity.** The panel of SNPs with a population prevalence of >10% were tested for
 494 association with reduced AIHH-induced plasticity in humans. These include 6 SNPs in genes
 495 involved in AIH cell signaling: (1) raphe chemosensitive cells (*PHOX2B*), (2) serotonin
 496 precursors in the central nervous system (tryptophan hydroxylase-2, *TPH-2*), (3) serotonin
 497 clearance enzyme (monoamine oxidase A, *MAOA*), (4) serotonin-2A receptors (*HTR2A*), (5)
 498 brain-derived neurotrophic factor (*BDNF*) and (6) TrkB receptors (*NTRK2*). A seventh
 499 dysfunctional SNP in neuroplasticity related gene, APOE (*APOE4*), was also tested for
 500 association.

501




502 **Figure 2: Relative (%-change from baseline) changes in diaphragm motor-evoked**
 503 **potential (MEP) amplitudes and mouth occlusion pressure (P0.1) in individuals with**
 504 ***BDNF*val/met (panels A and B) and *APOE*3/4 (panels C and D) SNP. No associations were**
 505 **observed between individuals with *BDNF*val/met and the change in MEP amplitudes (panel A)**
 506 **or P0.1 (panel B). Individuals with dysfunctional *APOE*3/4 allele were associated with a**
 507 **significantly lower AIHH-induced change in MEP amplitude (t=-2.28, p=0.048, panel C).**
 508 **However, no association between *APOE*3/4 and AIHH-induced P0.1 responses were observed**
 509 **(panel D). Δ=change. *p<0.05. Results expressed as mean ± SD.**

510 \blacklozenge = participant (S6) was identified as the most influential point (Cook's $D > 4$) in the %-change
 511 in diaphragm MEP amplitudes, therefore, the data was not included in group analyses.



512 **Figure 3: AIHH elicits phrenic long-term facilitation in hApoE3 but not hApoE4 knock-in**
513 **rats.** Panel A shows average traces of phrenic nerve amplitude for hApoE3 (n=4; gray) and
514 hApoE4 (n=3; black) knock-in rats, *p<0.050 vs baseline. Panel B phrenic burst amplitude (%-
515 change from baseline) in hApoE3 (gray circles) and hApoE4 (black circles) rats, +p<0.005
516 *versus* hApoE4. Δ=change. Results expressed as mean ± SD.



517 **Figure 4: Relationship between age and sex on the magnitude (%-change from baseline)**
 518 **of change in diaphragm motor-evoked potential amplitudes (MEP, panels A and B), and**
 519 **mouth occlusion pressure in 0.1 seconds (P0.1, panels C and D) following AIHH. No**
 520 **association between age and the magnitude of change in diaphragm MEP amplitudes was**
 521 **observed (panel A). Regardless of age, males (black line, panel B) had significantly greater**
 522 **responses in MEP amplitudes versus females (gray line, panel B). The magnitude of change in**
 523 **P0.1 reduced significantly with age (panel C); however, the decline was more pronounced in**
 524 **males ($r = -0.73, p = 0.036$, black line, panel D) versus females ($r = -0.29, p = 0.480$, gray line, panel**
 525 **D). Δ =change. $^*p < 0.05$. Results expressed as mean \pm SD.**
 526 \blacklozenge = participant (S6) was identified as the most influential point (Cook's $D > 4$) in the %-change
 527 in diaphragm MEP amplitudes, therefore, the data was not included in group analyses.

528 **Table 1. Demographics and SNP genotype classification details.** Includes individual participants' %-change from baseline in
 529 diaphragm motor-evoked potential amplitudes (MEP) and mouth occlusion pressure (P0.1) following AIHH and Sham exposures.
 530 Genotype letters in bold and underlined text indicate dysfunctional allele.

			SNP Classification										% -change from baseline in Diaphragm MEP		% -change from baseline in P0.1	
ID	Age	Sex	<i>BDNF</i> <i>rs6265</i> (Alt. Allele= <u>T</u>)	<i>APOE</i> <i>rs429358</i> (Alt. Allele= <u>C</u>)	<i>APOE</i> <i>rs7412</i> (Alt. Allele= <u>C</u>)	<i>APOE</i> classification (<i>rs429358+rs7412</i>)	<i>NTRK2</i> <i>rs1212171</i> (Alt. Allele= <u>T</u>)	<i>HTR2A</i> <i>rs6313</i> (Alt. Allele= <u>G</u>)	<i>PHOX2B</i> <i>rs16853571</i> (Alt. Allele= <u>C</u>)	<i>TPH2</i> <i>rs7305115</i> (Alt. Allele= <u>G</u>)	<i>MAOA</i> Male <i>rs5906957</i> (Alt. Allele= <u>A</u>)	<i>MAOA</i> Female <i>rs1137070</i> (Alt. Allele= <u>T</u>)	AIHH	Sham	AIHH	Sham
S01	40	M	CC	TT	<u>CC</u>	APO-E3/E3	<u>CT</u>	<u>GG</u>	AA	AA	GG		150.3	130.8	110.2	86.3
S02	29	F	<u>CT</u>	TT	<u>CC</u>	APO-E3/E3	<u>CT</u>	<u>AG</u>	AA	<u>AG</u>		CC	92.3	74.9	121.4	114.4
S03	28	F	CC	TT	<u>CC</u>	APO-E3/E3	<u>CT</u>	<u>AG</u>	AA	<u>GG</u>		<u>CT</u>	100.9	107.9	116.6	126.9
S04	27	F	<u>CT</u>	TT	<u>CT</u>	APO-E2/E3	<u>TT</u>	<u>AG</u>	AA	<u>AG</u>		<u>CT</u>	117.3	107.7	131.0	96.5
S06**	24	F	<u>CT</u>	TT	<u>CC</u>	APO-E3/E3	<u>TT</u>	<u>GG</u>	AA	AA		<u>CT</u>	215.5	95.9	123.2	78.8
S07	30	M	<u>CT</u>	TT	<u>CT</u>	APO-E2/E3	<u>CT</u>	AA	AA	<u>AG</u>	GG		156.0	147.0	86.6	114.8
S08	21	M	<u>CT</u>	<u>CT</u>	<u>CT</u>	APO-E2/E4	<u>CT</u>	<u>AG</u>	AA	<u>AG</u>	GG		142.7	65.5	145.9	98.1
S09	36	F	CC	<u>CT</u>	<u>CC</u>	<u>APO-E3/E4</u>	<u>CT</u>	<u>GG</u>	AA	<u>GG</u>		CC	69.3	52.6	105.7	113.1
S10	24	F	CC	<u>CT</u>	<u>CC</u>	<u>APO-E3/E4</u>	<u>CT</u>	<u>AG</u>	AA	<u>AG</u>		<u>TT</u>	85.3	127.0	119.3	98.0
S11	32	F	CC	<u>CT</u>	<u>CC</u>	<u>APO-E3/E4</u>	<u>TT</u>	<u>AG</u>	AA	<u>AG</u>		<u>CT</u>	91.4	63.6	83.5	125.9
S12	34	M	<u>CT</u>	TT	<u>CC</u>	APO-E3/E3	<u>CT</u>	<u>AG</u>	AA	<u>AG</u>	GG		137.7	103.8	61.9	75.2
S13	21	M	<u>CT</u>	<u>CT</u>	<u>CC</u>	<u>APO-E3/E4</u>	<u>CT</u>	<u>AG</u>	AA	<u>AG</u>	<u>AA</u>		110.7	93.4	171.6	109.7
S14	24	M	CC	TT	<u>CC</u>	APO-E3/E3	<u>CT</u>	<u>AG</u>	AA	<u>GG</u>	GG		106.4	89.9	158.6	98.7
S15	23	F	CC	TT	<u>CC</u>	APO-E3/E3	<u>CT</u>	<u>AG</u>	AA	<u>GG</u>		<u>CT</u>	94.2	70.3	93.7	69.5
S16	22	M	<u>CT</u>	<u>CT</u>	<u>CC</u>	<u>APO-E3/E4</u>	<u>TT</u>	AA	AA	<u>GG</u>	<u>AA</u>		120.2	82.4	193.4	126.0
S17	26	M	CC	TT	<u>CC</u>	APO-E3/E3	<u>TT</u>	<u>AG</u>	AA	<u>GG</u>	<u>AA</u>		164.4	87.5	112.6	94.7
S18	31	F	CC	TT	<u>CT</u>	APO-E2/E3	<u>TT</u>	<u>AG</u>	AA	<u>GG</u>		CC	141.4	73.4	91.1	104.9

** Outlier

531 **Table 2. Association of SNPs with %-change from baseline in diaphragm motor-evoked**
532 **potential amplitudes (MEP). *p<0.05.**

SNP	Estimate	Std. Error	t value	P value
<i>BDNF^{Val/met}</i>	0.2109	0.1928	1.0938	0.2789
<i>APOE^{3/4}</i>	-0.3802	0.1739	-2.1868	0.0476*
<i>NTRK²</i>	-0.1515	0.1633	-0.9279	0.3703
<i>HTR^{2A}</i>	0.1995	0.1889	1.0559	0.3102
<i>TPH²</i>	-0.2506	0.1234	-2.0312	0.0632
<i>MAOA (Male)</i>	0.0239	0.0934	0.2557	0.8084
<i>MAOA (Female)</i>	-0.2862	0.3171	-0.9026	0.4015

539

540 **Table 3. Association of SNPs with %-change from baseline in mouth occlusion pressure**
541 **in 0.1 seconds (P_{0.1}). *p<0.05.**

SNP	Estimate	Std. Error	t value	P value
<i>BDNF^{Val/met}</i>	0.0212	0.1435	0.1475	0.885
<i>APOE^{3/4}</i>	0.1997	0.1339	1.4908	0.1599
<i>NTRK²</i>	0.0411	0.1196	0.3433	0.7369
<i>HTR^{2A}</i>	0.1109	0.1369	0.8099	0.4325
<i>TPH²</i>	0.0002	0.1009	0.0017	0.9987
<i>MAOA (Male)</i>	0.0948	0.146	0.6496	0.5446
<i>MAOA (Female)</i>	-0.0133	0.1287	-0.1031	0.9213

543 REFERENCES

- 544 1. Gonzalez-Rothi, E.J., et al., *Intermittent hypoxia and neurorehabilitation*. J Appl Physiol (1985),
545 2015. **119**(12): p. 1455-65.
- 546 2. Vose, A.K., et al., *Therapeutic acute intermittent hypoxia: A translational roadmap for spinal*
547 *cord injury and neuromuscular disease*. Exp Neurol, 2022. **347**: p. 113891.
- 548 3. Welch, J.F., et al., *Acute intermittent hypercapnic-hypoxia elicits central neural respiratory motor*
549 *plasticity in humans*. J Physiol, 2022.
- 550 4. Vermeulen, T.D., et al., *Acute intermittent hypercapnic hypoxia and cerebral neurovascular*
551 *coupling in males and females*. Exp Neurol, 2020. **334**: p. 113441.
- 552 5. Puri, S., G. Panza, and J.H. Mateika, *A comprehensive review of respiratory, autonomic and*
553 *cardiovascular responses to intermittent hypoxia in humans*. Exp Neurol, 2021. **341**: p. 113709.
- 554 6. Lahiri, S. and R.G. DeLaney, *Stimulus interaction in the responses of carotid body chemoreceptor*
555 *single afferent fibers*. Respiratory Physiology, 1975. **24**: p. 249-266.
- 556 7. Kumar, P. and N.R. Prabhakar, *Peripheral chemoreceptors: function and plasticity of the carotid*
557 *body*. Comprehensive Physiology, 2012. **2**(1): p. 141-219.
- 558 8. Veasey, S.C., et al., *Response of serotonergic caudal raphe neurons in relation to specific motor*
559 *activities in freely moving cats*. J Neurosci, 1995. **15**(7 Pt 2): p. 5346-59.
- 560 9. Kadi, S.V. and A.I. Faden, *Neuroprotective strategies for traumatic brain injury: improving*
561 *clinical translation*. Int J Mol Sci, 2014. **15**(1): p. 1216-36.
- 562 10. Bodien, Y.G., et al., *Optimizing Outcome Assessment in Multicenter TBI Trials: Perspectives From*
563 *TRACK-TBI and the TBI Endpoints Development Initiative*. J Head Trauma Rehabil, 2018. **33**(3): p.
564 147-157.
- 565 11. Duncan, P.W., et al., *Body-weight-supported treadmill rehabilitation after stroke*. N Engl J Med,
566 2011. **364**(21): p. 2026-36.
- 567 12. Ashley, E.A., *The Precision Medicine Initiative: A New National Effort*. JAMA, 2015. **313**(21): p.
568 2119-2120.
- 569 13. Baker-Herman, T.L. and G.S. Mitchell, *Phrenic long-term facilitation requires spinal serotonin*
570 *receptor activation and protein synthesis*. J Neurosci, 2002. **22**(14): p. 6239-46.
- 571 14. Baker-Herman, T.L., et al., *BDNF is necessary and sufficient for spinal respiratory plasticity*
572 *following intermittent hypoxia*. Nat Neurosci, 2004. **7**(1): p. 48-55.
- 573 15. Fuller, D.D., et al., *Expression of hypoglossal long-term facilitation differs between substrains of*
574 *Sprague-Dawley rat*. Physiol Genomics, 2001. **4**(3): p. 175-81.
- 575 16. Baker-Herman, T.L., et al., *Differential expression of respiratory long-term facilitation among*
576 *inbred rat strains*. Respir Physiol Neurobiol, 2010. **170**(3): p. 260-7.
- 577 17. Chhibber, A. and L. Zhao, *ERbeta and ApoE isoforms interact to regulate BDNF-5-HT2A signaling*
578 *and synaptic function in the female brain*. Alzheimers Res Ther, 2017. **9**(1): p. 79.
- 579 18. Behan, M., A.G. Zabka, and G.S. Mitchell, *Age and gender effects on serotonin-dependent*
580 *plasticity in respiratory motor control*. Respir Physiol Neurobiol, 2002. **131**(1-2): p. 65-77.
- 581 19. Zabka, A.G., M. Behan, and G.S. Mitchell, *Long term facilitation of respiratory motor output*
582 *decreases with age in male rats*. J Physiol, 2001. **531**(Pt 2): p. 509-14.
- 583 20. Maskill, D., et al., *Motor cortical representation of the diaphragm in man*. The Journal of
584 Physiology, 1991. **443**(1): p. 105-121.
- 585 21. Welch, J.F., et al., *Reliability of diaphragmatic motor-evoked potentials induced by transcranial*
586 *magnetic stimulation*. J Appl Physiol (1985), 2020. **129**(6): p. 1393-1404.
- 587 22. Whitelaw, W.A., J.P. Derenne, and J. Milic-Emili, *Occlusion pressure as a measure of respiratory*
588 *center output in conscious man*. Respir Physiol, 1975. **23**(2): p. 181-99.

- 589 23. Devinney, M.J., et al., *Hypoxia-induced phrenic long-term facilitation: emergent properties*. Ann
590 N Y Acad Sci, 2013. **1279**: p. 143-153.
- 591 24. Fields, D.P. and G.S. Mitchell, *Spinal metaplasticity in respiratory motor control*. Front Neural
592 Circuits, 2015. **9**: p. 2.
- 593 25. Jha, A., et al., *Apolipoprotein E epsilon4 allele and outcomes of traumatic spinal cord injury*. The
594 journal of spinal cord medicine, 2008. **31**(2): p. 171-176.
- 595 26. Shi, Y., et al., *Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model*. J
596 Exp Med, 2019. **216**(11): p. 2546-2561.
- 597 27. Ghebremedhin, E., et al., *High frequency of apolipoprotein E epsilon4 allele in young individuals
598 with very mild Alzheimer's disease-related neurofibrillary changes*. Exp Neurol, 1998. **153**(1): p.
599 152-5.
- 600 28. Zlokovic, B.V., *Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease*.
601 JAMA Neurol, 2013. **70**(4): p. 440-4.
- 602 29. Petryshen, T.L., et al., *Population genetic study of the brain-derived neurotrophic factor (BDNF)
603 gene*. Molecular psychiatry, 2010. **15**(8): p. 810-815.
- 604 30. Verhagen, M., et al., *Meta-analysis of the BDNF Val66Met polymorphism in major depressive
605 disorder: effects of gender and ethnicity*. Molecular Psychiatry, 2010. **15**(3): p. 260-271.
- 606 31. Leech, K.A. and T.G. Hornby, *High-Intensity Locomotor Exercise Increases Brain-Derived
607 Neurotrophic Factor in Individuals with Incomplete Spinal Cord Injury*. J Neurotrauma, 2017.
608 **34**(6): p. 1240-1248.
- 609 32. Dale, E.A., et al., *Phrenic motor neuron TrkB expression is necessary for acute intermittent
610 hypoxia-induced phrenic long-term facilitation*. Experimental Neurology, 2017. **287**: p. 130-136.
- 611 33. Avdoshina, V., et al., *Single-nucleotide polymorphisms in TrkB and risk for depression: findings
612 from the women's interagency HIV study*. Journal of acquired immune deficiency syndromes
613 (1999), 2013. **64**(2): p. 138-141.
- 614 34. Lin, E., et al., *Gene-gene interactions of the brain-derived neurotrophic-factor and neurotrophic
615 tyrosine kinase receptor 2 genes in geriatric depression*. Rejuvenation Res, 2009. **12**(6): p. 387-
616 93.
- 617 35. Kennedy, A.P., et al., *A common TPH2 haplotype regulates the neural processing of a cognitive
618 control demand*. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012.
619 **159B**(7): p. 829-840.
- 620 36. Mosienko, V., M. Bader, and N. Alenina, *Chapter 35 - The serotonin-free brain: behavioral
621 consequences of Tph2 deficiency in animal models*, in *Handbook of Behavioral Neuroscience*, C.P.
622 Müller and K.A. Cunningham, Editors. 2020, Elsevier. p. 601-607.
- 623 37. Sanders-Bush, E., H. Fentress, and L. Hazelwood, *Serotonin 5-ht2 receptors: molecular and
624 genomic diversity*. Mol Interv, 2003. **3**(6): p. 319-30.
- 625 38. Lauriola, M., et al., *IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of
626 patients with Crohn's disease and correlation with sub-phenotypes*. Int J Mol Med, 2011. **27**(3):
627 p. 469-77.
- 628 39. Andreou, D., et al., *Polymorphisms in genes implicated in dopamine, serotonin and noradrenalin
629 metabolism suggest association with cerebrospinal fluid monoamine metabolite concentrations
630 in psychosis*. Behavioral and Brain Functions, 2014. **10**(1): p. 26.
- 631 40. Stopień, R., et al., *The c.1460C>T polymorphism of MAO-A is associated with the risk of
632 depression in postmenopausal women*. TheScientificWorldJournal, 2012. **2012**: p. 194845-
633 194845.
- 634 41. Kelly, M.N., et al., *Circadian clock genes and respiratory neuroplasticity genes oscillate in the
635 phrenic motor system*. Am J Physiol Regul Integr Comp Physiol, 2020. **318**(6): p. R1058-r1067.

- 636 42. Bach, K.B. and G.S. Mitchell, *Hypoxia-induced long-term facilitation of respiratory activity is*
637 *serotonin dependent*. *Respir Physiol*, 1996. **104**(2-3): p. 251-60.
- 638 43. Perim, R.R., et al., *Baseline Arterial CO2 Pressure Regulates Acute Intermittent Hypoxia-Induced*
639 *Phrenic Long-Term Facilitation in Rats*. *Front Physiol*, 2021. **12**: p. 573385.
- 640 44. Tadjalli, A., et al., *Systemic inflammation suppresses spinal respiratory motor plasticity via*
641 *mechanisms that require serine/threonine protein phosphatase activity*. *J Neuroinflammation*,
642 2021. **18**(1): p. 28.
- 643 45. Wu, M.C., et al., *Rare-variant association testing for sequencing data with the sequence kernel*
644 *association test*. *American journal of human genetics*, 2011. **89**(1): p. 82-93.
- 645 46. Team, R.C., *R: A language and environment for statistical computing*. 2021.
- 646 47. Strattan, L.E., et al., *Novel Influences of Sex and APOE Genotype on Spinal Plasticity and Recovery*
647 *of Function after Spinal Cord Injury*. *eNeuro*, 2021. **8**(2): p. ENEURO.0464-20.2021.
- 648 48. Kloiber, S., et al., *Variations in tryptophan hydroxylase 2 linked to decreased serotonergic activity*
649 *are associated with elevated risk for metabolic syndrome in depression*. *Molecular Psychiatry*,
650 2010. **15**(7): p. 736-747.
- 651 49. Egan, M.F., et al., *The BDNF val66met polymorphism affects activity-dependent secretion of*
652 *BDNF and human memory and hippocampal function*. *Cell*, 2003. **112**(2): p. 257-69.
- 653 50. Chen, Z.-Y., et al., *Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the*
654 *regulated secretory pathway*. *The Journal of neuroscience : the official journal of the Society for*
655 *Neuroscience*, 2005. **25**(26): p. 6156-6166.
- 656 51. Lu, B., P.T. Pang, and N.H. Woo, *The yin and yang of neurotrophin action*. *Nat Rev Neurosci*,
657 2005. **6**(8): p. 603-14.
- 658 52. Finan, J.D., et al., *The Influence of the Val66Met Polymorphism of Brain-Derived Neurotrophic*
659 *Factor on Neurological Function after Traumatic Brain Injury*. *J Alzheimers Dis*, 2018. **65**(4): p.
660 1055-1064.
- 661 53. McHughen, S.A., et al., *BDNF val66met polymorphism influences motor system function in the*
662 *human brain*. *Cereb Cortex*, 2010. **20**(5): p. 1254-62.
- 663 54. Keene, C.D., et al., *Apolipoprotein E isoforms and regulation of the innate immune response in*
664 *brain of patients with Alzheimer's disease*. *Current opinion in neurobiology*, 2011. **21**(6): p. 920-
665 928.
- 666 55. Huxtable, A.G., et al., *Systemic LPS induces spinal inflammatory gene expression and impairs*
667 *phrenic long-term facilitation following acute intermittent hypoxia*. *J Appl Physiol (1985)*, 2013.
668 **114**(7): p. 879-87.
- 669 56. Behan, M. and J.M. Wenninger, *Sex steroidal hormones and respiratory control*. *Respir Physiol*
670 *Neurobiol*, 2008. **164**(1-2): p. 213-21.
- 671 57. Behan, M., et al., *Sex steroid hormones and the neural control of breathing*. *Respir Physiol*
672 *Neurobiol*, 2003. **136**(2-3): p. 249-63.
- 673 58. Jensen, D., et al., *Chemoreflex control of breathing during wakefulness in healthy men and*
674 *women*. *J Appl Physiol (1985)*, 2005. **98**(3): p. 822-8.
- 675 59. Ahuja, D., et al., *Ventilatory sensitivity to carbon dioxide before and after episodic hypoxia in*
676 *women treated with testosterone*. *J Appl Physiol (1985)*, 2007. **102**(5): p. 1832-8.
- 677 60. Zabka, A.G., G.S. Mitchell, and M. Behan, *Conversion from testosterone to oestradiol is required*
678 *to modulate respiratory long-term facilitation in male rats*. *J Physiol*, 2006. **576**(Pt 3): p. 903-12.
- 679 61. Dougherty, B.J., E.S. Kopp, and J.J. Watters, *Nongenomic Actions of 17-beta Estradiol Restore*
680 *Respiratory Neuroplasticity in Young Ovariectomized Female Rats*. *J Neurosci*, 2017. **37**(28): p.
681 6648-6660.
- 682 62. Smith, M.D., L.S. Jones, and M.A. Wilson, *Sex differences in hippocampal slice excitability: role of*
683 *testosterone*. *Neuroscience*, 2002. **109**(3): p. 517-30.

- 684 63. Yang, D.W., et al., *Sexual dimorphism in the induction of LTP: critical role of tetanizing*
685 *stimulation*. Life Sci, 2004. **75**(1): p. 119-27.
- 686 64. Smith, M.J., et al., *Effects of ovarian hormones on human cortical excitability*. Ann Neurol, 2002.
687 **51**(5): p. 599-603.
- 688 65. Smith, M.J., et al., *Menstrual cycle effects on cortical excitability*. Neurology, 1999. **53**(9): p.
689 2069-72.
- 690 66. Nelson, N.R., I.M. Bird, and M. Behan, *Testosterone restores respiratory long term facilitation in*
691 *old male rats by an aromatase-dependent mechanism*. J Physiol, 2011. **589**(Pt 2): p. 409-21.
- 692 67. Mackiewicz, M., et al., *Age-related changes in adenosine metabolic enzymes in sleep/wake*
693 *regulatory areas of the brain*. Neurobiology of Aging, 2006. **27**(2): p. 351-360.
- 694 68. Murillo-Rodriguez, E., et al., *The diurnal rhythm of adenosine levels in the basal forebrain of*
695 *young and old rats*. Neuroscience, 2004. **123**(2): p. 361-370.
- 696 69. Zabka, A.G., M. Behan, and G.S. Mitchell, *Selected contribution: Time-dependent hypoxic*
697 *respiratory responses in female rats are influenced by age and by the estrus cycle*. J Appl Physiol
698 (1985), 2001. **91**(6): p. 2831-8.
- 699 70. Villa, A., et al., *Estrogens, Neuroinflammation, and Neurodegeneration*. Endocrine reviews, 2016.
700 **37**(4): p. 372-402.
- 701 71. Huxtable, A.G., et al., *Systemic inflammation impairs respiratory chemoreflexes and plasticity*.
702 Respir Physiol Neurobiol, 2011. **178**(3): p. 482-9.
- 703 72. Huxtable, A.G., et al., *Intermittent Hypoxia-Induced Spinal Inflammation Impairs Respiratory*
704 *Motor Plasticity by a Spinal p38 MAP Kinase-Dependent Mechanism*. J Neurosci, 2015. **35**(17): p.
705 6871-80.
- 706 73. Ghanadian, R., J.G. Lewis, and G.D. Chisholm, *Serum testosterone and dihydrotestosterone*
707 *changes with age in rat*. Steroids, 1975. **25**(6): p. 753-762.
- 708 74. Smith, E.R., et al., *Hormones and sexual behavior in relationship to aging in male rats*. Hormones
709 and Behavior, 1992. **26**(1): p. 110-135.
- 710 75. Bhasin, S., et al., *Testosterone Therapy in Men with Androgen Deficiency Syndromes: An*
711 *Endocrine Society Clinical Practice Guideline*. The Journal of Clinical Endocrinology &
712 Metabolism, 2010. **95**(6): p. 2536-2559.
- 713 76. Handelsman, D.J., et al., *Age-specific population centiles for androgen status in men*. Eur J
714 Endocrinol, 2015. **173**(6): p. 809-17.
- 715 77. Harman, S.M., et al., *Longitudinal effects of aging on serum total and free testosterone levels in*
716 *healthy men. Baltimore Longitudinal Study of Aging*. J Clin Endocrinol Metab, 2001. **86**(2): p.
717 724-31.
- 718 78. Hoffman, M.S., et al., *Spinal adenosine A2(A) receptor inhibition enhances phrenic long term*
719 *facilitation following acute intermittent hypoxia*. J Physiol, 2010. **588**(Pt 1): p. 255-66.
- 720 79. Hoffman, M.S., et al., *Phrenic long-term facilitation after acute intermittent hypoxia requires*
721 *spinal ERK activation but not TrkB synthesis*. J Appl Physiol (1985), 2012. **113**(8): p. 1184-93.
- 722 80. Marcianite, A.B. and G.S. Mitchell, *Aging Impairs Phrenic Long-Term Facilitation in Rats by an*
723 *Adenosine-Dependent Mechanism*. The FASEB Journal, 2022. **36**(S1).

724

725

726

727

728

